Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Frequency Therapeutics faces growing legal challenges

By Brian Buntz | June 15, 2021

Frequency TherapeuticsHearing loss drug developer Frequency Therapeutics (NASDAQ: FREQ) is the subject of a growing number of security fraud accusations on behalf of investors.

Earlier this year, things were looking up for the company’s lead product candidate, FX-322. But on March 23, Frequency Therapeutics announced that interim results suggested that FX-322 was not effective at improving mild to moderately severe sensorineural hearing loss in a Phase 2a study compared to placebo. Previous results from a smaller study had been more positive.

The company’s stock fell from a high of $55.01 on Feb. 19 to $9.55 in mid-day trading on June 15.

Among the law firms filing lawsuits against Frequency Therapeutics is Robbins LLP (San Diego), which recently filed a class-action lawsuit for purchasers of Frequency Therapeutics stock between Nov. 16, 2020 and March 22. That lawsuit alleges that the company misrepresented its FX-322 experimental drug in earnings calls, press releases, SEC filings and pharmaceutical presentations before March 23. Also, before that date, the company’s CEO David Lucchino sold more than 350,000 shares of its stock, netting more than $10.5 million.

Other law firms that are pursuing similar class action litigation against Frequency Therapeutics include the following:

  • Berger Montague (Philadelphia).
  • Bragar Eagel & Squire (New York City).
  • Portnoy Law Firm (Los Angeles).
  • Schall Law Firm (Los Angeles).
  • Robbins Geller Rudman & Dowd (San Diego).
  • Levi & Korsinsky (New York City).
  • Bronstein, Gewirtz & Grossman (New York City).
  • Frank R. Cruz (Los Angeles).
  • Howard G. Smith (Bensalem, Pa.).
  • Glancy Prongay & Murray LLP (Los Angeles).
  • Law Offices of Vincent Wong (New York City).
  • Klein Law Firm (New York City).

A Frequency Therapeutics spokesperson said the firm has no comment on this subject.

Frequency Therapeutics has drawn on research from noted scientist Robert Langer of MIT and serial entrepreneur Jeff Karp. Karp is also a professor of medicine at Brigham and Women’s Hospital at Harvard Medical School.

Langer serves on the board of Frequency Therapeutics.


Filed Under: ENT drugs
Tagged With: David Lucchino, Frequency Therapeutics, FX-322, security fraud allegations
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Otonomy
Otonomy gives up on experimental tinnitus drug after disappointing Phase 2 trial
Pfizer
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Decibel Therapeutics
Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO
Otonomy
Investigational tinnitus drug shows promise in Phase 1/2 study

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50